Dr. Antony Ruggeri
Claim this profileAurora Cancer Care-Milwaukee West
Studies Parotid Gland Cancer
Studies Colon Cancer
14 reported clinical trials
57 drugs studied
Area of expertise
1Parotid Gland Cancer
Stage IV
Stage III
Stage I
2Colon Cancer
Stage IV
Stage III
BRAF negative
Affiliated Hospitals
Clinical Trials Antony Ruggeri is currently running
Selumetinib + Olaparib
for Ovarian and Endometrial Cancer
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.
Recruiting1 award Phase 2
Ipatasertib + Chemotherapy
for Cancer
This phase II ComboMATCH treatment trial tests the usual treatment of chemotherapy (paclitaxel) plus ipatasertib in patients with solid tumor cancers that that cannot be removed by surgery (unresectable), has spread to nearby tissue or lymph nodes (locally advanced) or from where it first started (primary site) to other places in the body (metastatic), and has PTEN and AKT genetic changes. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Targeted therapy, such as Ipatasertib, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of ipatasertib to paclitaxel in solid tumors with PTEN and AKT genetic changes could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression). Researchers hope to learn if paclitaxel plus ipatasertib will shrink this type of cancer or stop its growth.
Recruiting1 award Phase 2
More about Antony Ruggeri
Clinical Trial Related4 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Antony Ruggeri has experience with
- Paclitaxel
- Olaparib
- Capecitabine
- Fluorouracil
- Cisplatin
- Irinotecan
Breakdown of trials Antony Ruggeri has run
Parotid Gland Cancer
Colon Cancer
Cancer
Solid Tumors
Colorectal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Antony Ruggeri specialize in?
Is Antony Ruggeri currently recruiting for clinical trials?
Are there any treatments that Antony Ruggeri has studied deeply?
What is the best way to schedule an appointment with Antony Ruggeri?
What is the office address of Antony Ruggeri?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.